



MARYLAND MEDICAID PHARMACY PROGRAM

No. 160
December 1, 2015

ADVISORY

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MMPP representative at 410-767-1455.

Brand Abilify® Removal from DAW 6 Program

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that effective **Wednesday, December 16, 2015; brand Abilify® (aripiprazole) will no longer be preferred** over their generic equivalents. Claims for aripiprazole will be handled in the same manner as claims for other multisource drugs. Fee-for-service Medicaid claims for brand Abilify® will adjudicate only if there is a prior authorization based on an approved Medwatch form which can be found at the following link:

<https://mmcp.dhmh.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

Please refer to our website for a complete list of the Preferred Drug List (PDL) at the following links:

<https://mmcp.dhmh.maryland.gov/pap/SitePages/druglist.aspx>

<http://www.epocrates.com/> **

**Epocrates is updated weekly.